Date: 2018-10-18
Type of information: Production agreement
Compound: tumor infiltrating lymphocyte (TIL)
Company: Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY)
Therapeutic area: Technology - Services
Type agreement:
- manufaturing - bioproduction
Action mechanism: tumor infiltrating lymphocyte (TIL)
Disease:
Details:
- • On October 18, 2018, Iovance Biotherapeutics and MaSTherCell, a subsidiary of Orgenesis, announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture tumor infiltrating lymphocyte (TIL) for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.
Financial terms:
Latest news:
Is general: Yes
